Schuerman Lode, Borys Dorota, Hoet Bernard, Forsgren Arne, Prymula Roman
GlaxoSmithKline Biologicals, Rixensart/Wavre, Belgium.
Vaccine. 2009 Sep 25;27(42):5748-54. doi: 10.1016/j.vaccine.2009.07.070. Epub 2009 Aug 8.
Acute otitis media (AOM), one of the most common childhood diseases, is associated with a substantial medical, social and economic burden. Non-typeable Haemophilus influenzae (NTHi) and Streptococcus pneumoniae are the two main causes of bacterial OM. The 7-valent pneumococcal CRM(197)-conjugate vaccine (7vCRM, Prevnar/Prevenar, Wyeth) demonstrated efficacy against AOM caused by vaccine pneumococcal serotypes. Protection against overall AOM was also observed with an 11-valent pneumococcal protein D-conjugate vaccine (11Pn-PD) in the Pneumococcal Otitis Efficacy Trial (POET). Following POET, an optimized 10-valent pneumococcal non-typeable H. influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix, GlaxoSmithKline Biologicals) was developed. This vaccine includes serotypes 1, 5, and 7F, in addition to those already included in 7vCRM, and was recently licensed in Europe for active immunization against invasive disease and AOM caused by S. pneumoniae in infants and children from 6 weeks up to 2 years of age. The use of protein D as carrier protein permits avoidance of possible interferences known to occur with some conjugate vaccines, and has the added potential benefit of providing protection against NTHi. This review seeks to highlight the recent advances in the field of OM vaccination, with a focus on data regarding the recently licensed PHiD-CV.
急性中耳炎（AOM）是儿童期最常见的疾病之一，会带来巨大的医疗、社会和经济负担。不可分型流感嗜血杆菌（NTHi）和肺炎链球菌是细菌性中耳炎的两个主要病因。7价肺炎球菌CRM(197)结合疫苗（7vCRM，沛儿/Prevenar，惠氏）已证明对由疫苗肺炎球菌血清型引起的AOM有效。在肺炎球菌性中耳炎疗效试验（POET）中，11价肺炎球菌蛋白D结合疫苗（11Pn-PD）也显示出对总体AOM的保护作用。继POET之后，研发出了优化的10价肺炎球菌-不可分型流感嗜血杆菌蛋白D结合疫苗（PHiD-CV；施慧达，葛兰素史克生物制品公司）。该疫苗除了包含7vCRM中已有的血清型外，还包括血清型1、5和7F，最近在欧洲获得许可，用于对6周龄至2岁婴幼儿进行主动免疫，预防由肺炎链球菌引起的侵袭性疾病和AOM。使用蛋白D作为载体蛋白可避免一些结合疫苗已知会出现的可能干扰，并且还有额外的潜在益处，即提供针对NTHi的保护。本综述旨在突出中耳炎疫苗领域的最新进展，重点关注有关最近获得许可的PHiD-CV的数据。
